Ann: Progress towards clinical development of IMP761, page-13

Most certainly they should be seeking business development deals for all programs. Scaling up IMP761 manufacturing in a GMP setting does not tell me they are close to a deal. At this stage, that would be more appropriate for a large commercial organization to take on. If I had to guess, they’re looking for money to go it alone if the right deal doesn’t come along. Obviously if the NKTR deal was offered, we’d be reading about a new licensing deal, rather than cell selection for scale up. They have assets to shop and waiting for the best deal and partner is fine by me.